Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
Clinical trial NCT03619213 · COMPLETED
Trial details
- NCT number
- NCT03619213
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-27
- Primary completion
- 2022-03-27
- Enrollment
- 6263
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.